SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

The Goal of This Research Program Is to Develop a Self-Administered Intranasal Tlr4 Agonist to Treat Allergic Rhinitis. Unlikeantigen-Specific Therapy
Award last edited on: 5/8/2023

Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$1,836,454
Award Phase
2
Solicitation Topic Code
91
Principal Investigator
Juhienah Khalaf

Company Information

Inimmune Corporation

1121 East Broadway Street Unit 121
Missoula, MT 59802
   (406) 360-2732
   info@inimmune.com
   www.inimmune.com
Location: Single
Congr. District: 01
County: Missoula

Phase I

Contract Number: N/A
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2021
Phase I Amount
$1
Direct to Phase II

Phase II

Contract Number: 75N93021C00044
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2021
Phase II Amount
$1,836,453
The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis. Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.